Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and the development of Chimeric Antigen Receptor T cell (CAR T) therapies for cancer, announced that 350 registered shares benefit from a double voting right as of May 25, 2022. As a result, the Company’s total number of voting rights is now 24,962,331.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures – Modified on 25 May 2022 following the Double Voting Rights:
|Total amount of share capital (EUR)||78,584,224.33|
|Total Number of shares with single voting rights||20,225,581|
|Total Number of shares with double voting rights||2,368,375|
|Total Number of Shares||22,593,956|
|Total of voting rights||24,962,331|
|Total number of attributed warrants||1,997,190|
|Total number of shares with voting rights that could be created following the exercise of the attributed warrants||1,997,190|
|Total number of diluted shares (Outstanding shares + Warrants)||24,591,146|
|Total number of diluted shares with voting rights||26,959,521|
Contact person for regulated information (financial, transparency)
By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO): email@example.com.
Further questions about the content of this release can be sent to firstname.lastname@example.org.